Literature DB >> 8980992

Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.

D Simon1, J Köhrle, C Schmutzler, K Mainz, C Reiners, H D Röher.   

Abstract

Retinoic acids (RA) regulate growth and differentiation of normal epithelial tissue. They have been employed in anticancer treatment and showed positive effects in hematopoetic and various epithelial tumors. Experimental data with follicular thyroid tumor cells showed strong evidence of induction of differentiated cell function and antiproliferative effects. Based on these data a consecutive series of 10 patients with advanced thyroid carcinoma were treated with 13-cis-retinoic acid (Roaccutan) 1.5 mg/kg body weight for six weeks. Follow-up demonstrated renewed uptake of radioiodine in 4 of 10 patients allowing performance of further radioiodine therapy. Reduction in tumor size due to antiproliferative effects of RA could not yet be verified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980992     DOI: 10.1055/s-0029-1211692

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  12 in total

Review 1.  Regulation of sodium/iodide symporter.

Authors:  S M Jhiang
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  The management of metastatic differentiated thyroid carcinoma.

Authors:  S I Sherman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 3.  Alternative medical treatment for radioiodine-refractory thyroid cancers.

Authors:  Jin Chul Paeng; Keon Wook Kang; Do Joon Park; So Won Oh; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2011-09-17

Review 4.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

5.  Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.

Authors:  T Saito; T Endo; A Kawaguchi; M Ikeda; R Katoh; A Kawaoi; A Muramatsu; T Onaya
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

6.  Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma.

Authors:  S Mendes Coelho; R Corbo; A Buescu; D P Carvalho; M Vaisman
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

7.  Rational management of differentiated thyroid cancer.

Authors:  Birendra Kishore Das; Biswa Mohan Biswal; Venkata Murali Krishna Bhavaraju
Journal:  Malays J Med Sci       Date:  2006-07

Review 8.  Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.

Authors:  Ji Min Oh; Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

9.  The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation.

Authors:  Hani Alotaibi; Merve Tuzlakoğlu-Öztürk; Uygar Halis Tazebay
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

10.  Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience.

Authors:  Nishikant Damle; Manish Patnecha; Praveen Kumar; Sagar Maharjan; Chandrasekhar Bal
Journal:  Indian J Nucl Med       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.